葡萄膜恶性黑色素瘤治疗新进展  

Progress on treatment of uveal melanoma

作　　者：唐飞[1] 甘露 何为民[3] 

机构地区：[1]四川大学华西医院上锦南府医院眼科,中国四川省成都市611731 [2]中航工业成都363医院眼科,中国四川省成都市610041 [3]四川大学华西医院眼科,中国四川省成都市610041

出　　处：《国际眼科杂志》2017年第2期254-258,共5页International Eye Science

摘　　要：葡萄膜恶性黑色素瘤(uveal melanoma,UM)是成人最常见的原发性眼内恶性肿瘤。虽然目前治疗手段多种多样,眼球摘除术仍是本病的传统治疗,但手术摘除眼球并不能完全控制肿瘤的远处转移。对于伴全身转移的患者,据30a来的统计,生存率仍很低。近年来许多研究致力于靶向治疗、免疫治疗、放射治疗,并取得了可喜的效果,本文对相关研究进行综述。Uveal melanoma（UM） is the most common primary intraocular malignant tumor of adult.The traditional treatment is enucleation,but it cannot completely avoid metastasis,and on the contrary,it stimulates to distant metastasis of tumor cells to some extent.According to the statistic of latest 30 a,survival rates of UM patients with metastasis is still very low.Recently,many researches devoted to targeted therapy,immune therapy and radiotherapy,which have achieved gratifying results.We summarized these relative researches in this paper.

关 键 词：葡萄膜恶性黑色素瘤 靶向治疗 免疫治疗 放射治疗 

分 类 号：R739.7[医药卫生—肿瘤]